Australia markets closed

Shenyang Xingqi Pharmaceutical Co.,Ltd. (300573.SZ)

Shenzhen - Shenzhen Delayed price. Currency in CNY
Add to watchlist
167.29-5.69 (-3.29%)
At close: 03:04PM CST

Shenyang Xingqi Pharmaceutical Co.,Ltd.

No. 68, Sishui Street
Dongling District
Shenyang 110163
China
86 40 0613 5599
https://www.sinqi.com

Sector(s)Healthcare
IndustryMedical Instruments & Supplies
Full-time employees1,995

Key executives

NameTitlePayExercisedYear born
Ms. E. GaoMD, GM & Non-Independent DirectorN/AN/A1974
Mr. Shaoyao ZhangDeputy Chairman, Deputy GM & Secretary of the BoardN/AN/A1970
Ms. Yanan ChengDeputy GM, Financial Director, CFO & Non-Independent DirectorN/AN/A1974
Mr. Chunhua LiDirector of the Administrative Management Department & DirectorN/AN/A1977
Mr. Qiang YangHead of R&D Center, Deputy GM & DirectorN/AN/A1984
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CNY.

Description

Shenyang Xingqi Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of ophthalmic medications in the People's Republic of China. The company offers corneal, anti-bacteria, artificial tears, anti-inflammation, anti-allergic, mydriactics, anti-fatigue, and dry eye treatment products. It also engages in the technology development, technical consultation, investment, and eye hospital businesses, as well as production and wholesale of pharmaceuticals. The company was founded in 1977 and is headquartered in Shenyang, the People's Republic of China.

Corporate governance

Shenyang Xingqi Pharmaceutical Co.,Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.